Galapagos

• Kempen & Co has advised Galapagos on its sale of Fidelta to Selvita for a total consideration of €31.2 million 
• Galapagos is a leading fully integrated biopharmaceutical company, and as such Fidelta’s CRO activities no longer fit with Galapagos’ strategy
• The scope of services provided by Fidelta is complementary to Selvita’s offerings and this transaction will create one of the largest preclinical contract research organisations in Europe
• This transaction further builds on Kempen & Co's decade long strong relationship with Galapagos, with Kempen & Co leading Galapagos’ Euronext IPO in May 2005 and assisting in several follow-on as well as M&A transactions thereafter

Fidelta is a contract research organisation within the Galapagos Group of companies, with core scientific competences in inflammation, fibrosis, and anti-infectives. It currently employs 181 employees, including over 150 highly experienced scientists, providing integrated drug discovery services in the biotech and pharmaceutical industry, with a proven track record of accomplished laboratory projects over many years. Fidelta is located in state-of-the art R&D facilities in Zagreb, Croatia which offer almost 6,000 m2 of research space. 

Upon completion of the acquisition, Fidelta will be fully consolidated under the Selvita Group, and will continue to operate under the Fidelta name.

In 2020, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: 

• Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
• Lead Manager in the USD 85.0 million Nasdaq Initial Public Offering by Galecto 
• Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
• Bookrunner in the USD 245 million Nasdaq Initial Public Offering by Curevac
• Co-Manager in the USD 49.0 million US Public Offering by Centogene
• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
• Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
• Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
• Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp., thereby becoming a Nasdaq listed company and securing USD 253 million
• Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
• Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
• Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
• Co-Manager in the USD 862 million Global Offering by argenx
• Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides
• Co-Manager in the USD 154 million Global Offering of DBV Therapeutics
• Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical